Thyrocare Technologies Limited's Board of Directors, in a meeting held on May 7, 2026, recommended a final dividend of ₹7.00 per equity share for the financial year 2025-26, subject to shareholder approval at the upcoming Annual General Meeting (AGM). This, combined with the interim dividend already paid, brings the total dividend for FY26 to ₹9.33 per share. The Board also approved the appointment of M/s. Price Waterhouse Chartered Accountants LLP as the Statutory Auditors for a five-year term, commencing from the conclusion of the 26th AGM in 2026 until the 31st AGM in 2031. M/s. Jitender Navneet & Co. were appointed as Cost Auditors for the financial year 2026-27. Key personnel changes were also approved. Mr. Rahul Franklin Guha was re-appointed as Chairman, Managing Director & CEO for another five-year term starting May 4, 2027. Additionally, Mr. Uday Patel Kadam and Mr. Gaurav Verma were appointed as Additional Directors (Non-Executive, Non-Independent) effective May 8, 2026. The Board noted the resignations of Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah, both Non-Executive, Non-Independent Directors, effective May 7, 2026, due to other commitments. Furthermore, the company approved an investment of up to ₹5.50 crore in its wholly-owned subsidiary, Think Health Diagnostics Private Limited, to support its operations. The Memorandum of Association (MOA) of the company will also be altered to align with the Companies Act, 2013, and broaden its scope within the healthcare and diagnostics ecosystem.
